Composition and method for reducing neutropenia
Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.
1. A method of reducing neutropenia in a subject, comprising administering plinabulin or a pharmaceutically acceptable salt thereof to the subject,
wherein the neutropenia is induced by administration of a first chemotherapeutic composition comprising one or more chemotherapeutic agents,
wherein the first chemotherapeutic composition comprises one or more agents selected from the group consisting of cyclophosphamide, ifosamide, cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, satraplatin, topotecan, doxorubicin, epirubicin, daunorubicin, valrubicin, and pharmaceutically acceptable salts thereof,
or by administration of radiation therapy.
2. The method of claim 1 , wherein the first chemotherapeutic composition does not comprise a taxane.
3. The method of claim 1 , comprising administering one or more additional chemotherapeutic compositions to the subject.
4. The method of claim 1 , wherein the first chemotherapeutic composition comprises a single chemotherapeutic agent.
5. The method of claim 1 , wherein the first chemotherapeutic composition comprises two or more chemotherapeutic agents.
6. The method of claim 3 , wherein the at least one of the one or more additional chemotherapeutic compositions comprises docetaxel.
7. The method of claim 3 , wherein at least one of the one or more additional chemotherapeutic compositions comprises one or more taxanes selected from the group consisting of docetaxel, paclitaxel, and cabazitaxel.
8. The method of claim 1 , wherein the first chemotherapeutic composition comprises cyclophosphamide.
9. The method of claim 1 , wherein the first chemotherapeutic composition comprises cisplatin.
10. The method of claim 1 , wherein the first chemotherapeutic composition comprises doxorubicin.
11. The method of claim 1 , wherein the first chemotherapeutic composition comprises topotecan.
12. The method of claim 1 , comprising administering plinabulin prior to administering the first chemotherapeutic composition.
13. The method of claim 12 , wherein the plinabulin is administered in the range of about 1 minute to 24 hours prior to administration of the first chemotherapeutic composition.
14. The method of claim 1 , comprising administering plinabulin after administering the first chemotherapeutic composition.
15. The method of claim 14 , wherein the plinabulin is administered in the range of about 1 minute to 24 hours after administration of the first chemotherapeutic composition.
16. The method of claim 1 , wherein the plinabulin and the first chemotherapeutic composition are co-administered.
17. The method of claim 3 , comprising:
administering plinabulin prior to administration of the first chemotherapeutic composition; and
administering the additional one or more chemotherapeutic compositions after administration of the first chemotherapeutic composition.
18. The method of claim 3 , comprising:
administering the first chemotherapeutic composition prior to administration of the plinabulin; and
administering the additional one or more chemotherapeutic compositions after administration of the plinabulin.
19. The method of claim 3 , comprising:
administering the first chemotherapeutic composition prior to administration of the additional one or more chemotherapeutic compositions; and
administering the plinabulin after administration of the additional one or more chemotherapeutic agents.
20. The method of claim 17 , wherein a period of time between administration of each of plinabulin, the first chemotherapeutic composition, and the additional one or more chemotherapeutic compositions is independently selected between about 1 minute and 24 hours.
21. The method of claim 1 , comprising administering radiation therapy to the subject.
22. The method of claim 1 , further comprising identifying the subject as suffering from neutropenia.
23. The method of claim 1 , wherein the neutropenia induced by the first chemotherapeutic composition is a grade 3 or 4 neutropenia.
24. The method of claim 1 , further comprising identifying the subject as being at risk for developing neutropenia.
25. The method of claim 1 , wherein said reducing neutropenia further comprises reducing the likelihood of onset of, or reducing the severity of, neutropenia in the subject.